Review



mrtx1257  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    MedChemExpress mrtx1257
    N17350 broadly kills cancer cells while preserving immune cells (A and B) Various cancer cell lines and primary cancer cells from OvCa patients were treated with increasing doses of N17350 for 24 h, and the EC50 was determined (n = 2–6/dose). (A) Representative killing curves for OvCa patient cancer cells (left), lung cancer cells with distinct KRAS variants (middle), and other tumor types (right). (B) Summary of EC50 values (left) and cancer-cell-type origin (right). (C) Representative tumor growth curve for NCI-H358 and NCI-H2122 tumors (non-small cell lung cancer) treated with N17350 (400 μg/100 mm 3 , intra-tumoral), <t>MRTX1257</t> (100 mg/kg, oral, daily), or carboplatin (100 mg/kg, intraperitoneal, days 0 and 7); n = 5 mice/group. (D) N17350 efficacy 72 h after a single intra-tumoral injection across various xenograft models; n = 5–7 mice/group. (E) Cancer and non-cancer cells were isolated from OvCa patients, treated with N17350 (500 nM), doxorubicin (10 μM), or oxaliplatin (100 μM) for 24 h, and cell viability was assessed; n = 2–3/patient, n = 31–39 patients/group. (F) Representative N17350 killing curve (left) and eXEC50 values (right) for cancer cells and CD45 + immune cells isolated from the same tumor of OvCa patients ( n = 3/dose across patients). EC50 values for immune cells were assigned as >10,000 nM, as the maximal tested dose failed to achieve a response plateau, precluding accurate curve fitting. ∗ p < 0.05, two-way ANOVA (C and E), Student’s t test: unpaired (D) and paired (F). Results are mean ± SEM. Arrows indicate N17350 treatment. All replicates are independent biological replicates.
    Mrtx1257, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 6 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mrtx1257/product/MedChemExpress
    Average 93 stars, based on 6 article reviews
    mrtx1257 - by Bioz Stars, 2026-02
    93/100 stars

    Images

    1) Product Images from "Developing a therapeutic elastase that stimulates anti-tumor immunity by selectively killing cancer cells"

    Article Title: Developing a therapeutic elastase that stimulates anti-tumor immunity by selectively killing cancer cells

    Journal: Cell Reports Medicine

    doi: 10.1016/j.xcrm.2025.102446

    N17350 broadly kills cancer cells while preserving immune cells (A and B) Various cancer cell lines and primary cancer cells from OvCa patients were treated with increasing doses of N17350 for 24 h, and the EC50 was determined (n = 2–6/dose). (A) Representative killing curves for OvCa patient cancer cells (left), lung cancer cells with distinct KRAS variants (middle), and other tumor types (right). (B) Summary of EC50 values (left) and cancer-cell-type origin (right). (C) Representative tumor growth curve for NCI-H358 and NCI-H2122 tumors (non-small cell lung cancer) treated with N17350 (400 μg/100 mm 3 , intra-tumoral), MRTX1257 (100 mg/kg, oral, daily), or carboplatin (100 mg/kg, intraperitoneal, days 0 and 7); n = 5 mice/group. (D) N17350 efficacy 72 h after a single intra-tumoral injection across various xenograft models; n = 5–7 mice/group. (E) Cancer and non-cancer cells were isolated from OvCa patients, treated with N17350 (500 nM), doxorubicin (10 μM), or oxaliplatin (100 μM) for 24 h, and cell viability was assessed; n = 2–3/patient, n = 31–39 patients/group. (F) Representative N17350 killing curve (left) and eXEC50 values (right) for cancer cells and CD45 + immune cells isolated from the same tumor of OvCa patients ( n = 3/dose across patients). EC50 values for immune cells were assigned as >10,000 nM, as the maximal tested dose failed to achieve a response plateau, precluding accurate curve fitting. ∗ p < 0.05, two-way ANOVA (C and E), Student’s t test: unpaired (D) and paired (F). Results are mean ± SEM. Arrows indicate N17350 treatment. All replicates are independent biological replicates.
    Figure Legend Snippet: N17350 broadly kills cancer cells while preserving immune cells (A and B) Various cancer cell lines and primary cancer cells from OvCa patients were treated with increasing doses of N17350 for 24 h, and the EC50 was determined (n = 2–6/dose). (A) Representative killing curves for OvCa patient cancer cells (left), lung cancer cells with distinct KRAS variants (middle), and other tumor types (right). (B) Summary of EC50 values (left) and cancer-cell-type origin (right). (C) Representative tumor growth curve for NCI-H358 and NCI-H2122 tumors (non-small cell lung cancer) treated with N17350 (400 μg/100 mm 3 , intra-tumoral), MRTX1257 (100 mg/kg, oral, daily), or carboplatin (100 mg/kg, intraperitoneal, days 0 and 7); n = 5 mice/group. (D) N17350 efficacy 72 h after a single intra-tumoral injection across various xenograft models; n = 5–7 mice/group. (E) Cancer and non-cancer cells were isolated from OvCa patients, treated with N17350 (500 nM), doxorubicin (10 μM), or oxaliplatin (100 μM) for 24 h, and cell viability was assessed; n = 2–3/patient, n = 31–39 patients/group. (F) Representative N17350 killing curve (left) and eXEC50 values (right) for cancer cells and CD45 + immune cells isolated from the same tumor of OvCa patients ( n = 3/dose across patients). EC50 values for immune cells were assigned as >10,000 nM, as the maximal tested dose failed to achieve a response plateau, precluding accurate curve fitting. ∗ p < 0.05, two-way ANOVA (C and E), Student’s t test: unpaired (D) and paired (F). Results are mean ± SEM. Arrows indicate N17350 treatment. All replicates are independent biological replicates.

    Techniques Used: Preserving, Injection, Isolation



    Similar Products

    mrtx1257  (MedChemExpress)
    93
    MedChemExpress mrtx1257
    N17350 broadly kills cancer cells while preserving immune cells (A and B) Various cancer cell lines and primary cancer cells from OvCa patients were treated with increasing doses of N17350 for 24 h, and the EC50 was determined (n = 2–6/dose). (A) Representative killing curves for OvCa patient cancer cells (left), lung cancer cells with distinct KRAS variants (middle), and other tumor types (right). (B) Summary of EC50 values (left) and cancer-cell-type origin (right). (C) Representative tumor growth curve for NCI-H358 and NCI-H2122 tumors (non-small cell lung cancer) treated with N17350 (400 μg/100 mm 3 , intra-tumoral), <t>MRTX1257</t> (100 mg/kg, oral, daily), or carboplatin (100 mg/kg, intraperitoneal, days 0 and 7); n = 5 mice/group. (D) N17350 efficacy 72 h after a single intra-tumoral injection across various xenograft models; n = 5–7 mice/group. (E) Cancer and non-cancer cells were isolated from OvCa patients, treated with N17350 (500 nM), doxorubicin (10 μM), or oxaliplatin (100 μM) for 24 h, and cell viability was assessed; n = 2–3/patient, n = 31–39 patients/group. (F) Representative N17350 killing curve (left) and eXEC50 values (right) for cancer cells and CD45 + immune cells isolated from the same tumor of OvCa patients ( n = 3/dose across patients). EC50 values for immune cells were assigned as >10,000 nM, as the maximal tested dose failed to achieve a response plateau, precluding accurate curve fitting. ∗ p < 0.05, two-way ANOVA (C and E), Student’s t test: unpaired (D) and paired (F). Results are mean ± SEM. Arrows indicate N17350 treatment. All replicates are independent biological replicates.
    Mrtx1257, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mrtx1257/product/MedChemExpress
    Average 93 stars, based on 1 article reviews
    mrtx1257 - by Bioz Stars, 2026-02
    93/100 stars
    		  Buy from Supplier
    mrtx1257 cayman  (MedChemExpress)
    93
    MedChemExpress mrtx1257 cayman
    N17350 broadly kills cancer cells while preserving immune cells (A and B) Various cancer cell lines and primary cancer cells from OvCa patients were treated with increasing doses of N17350 for 24 h, and the EC50 was determined (n = 2–6/dose). (A) Representative killing curves for OvCa patient cancer cells (left), lung cancer cells with distinct KRAS variants (middle), and other tumor types (right). (B) Summary of EC50 values (left) and cancer-cell-type origin (right). (C) Representative tumor growth curve for NCI-H358 and NCI-H2122 tumors (non-small cell lung cancer) treated with N17350 (400 μg/100 mm 3 , intra-tumoral), <t>MRTX1257</t> (100 mg/kg, oral, daily), or carboplatin (100 mg/kg, intraperitoneal, days 0 and 7); n = 5 mice/group. (D) N17350 efficacy 72 h after a single intra-tumoral injection across various xenograft models; n = 5–7 mice/group. (E) Cancer and non-cancer cells were isolated from OvCa patients, treated with N17350 (500 nM), doxorubicin (10 μM), or oxaliplatin (100 μM) for 24 h, and cell viability was assessed; n = 2–3/patient, n = 31–39 patients/group. (F) Representative N17350 killing curve (left) and eXEC50 values (right) for cancer cells and CD45 + immune cells isolated from the same tumor of OvCa patients ( n = 3/dose across patients). EC50 values for immune cells were assigned as >10,000 nM, as the maximal tested dose failed to achieve a response plateau, precluding accurate curve fitting. ∗ p < 0.05, two-way ANOVA (C and E), Student’s t test: unpaired (D) and paired (F). Results are mean ± SEM. Arrows indicate N17350 treatment. All replicates are independent biological replicates.
    Mrtx1257 Cayman, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mrtx1257 cayman/product/MedChemExpress
    Average 93 stars, based on 1 article reviews
    mrtx1257 cayman - by Bioz Stars, 2026-02
    93/100 stars
    		  Buy from Supplier
    internal standard mrtx  (MedChemExpress)
    93
    MedChemExpress internal standard mrtx
    N17350 broadly kills cancer cells while preserving immune cells (A and B) Various cancer cell lines and primary cancer cells from OvCa patients were treated with increasing doses of N17350 for 24 h, and the EC50 was determined (n = 2–6/dose). (A) Representative killing curves for OvCa patient cancer cells (left), lung cancer cells with distinct KRAS variants (middle), and other tumor types (right). (B) Summary of EC50 values (left) and cancer-cell-type origin (right). (C) Representative tumor growth curve for NCI-H358 and NCI-H2122 tumors (non-small cell lung cancer) treated with N17350 (400 μg/100 mm 3 , intra-tumoral), <t>MRTX1257</t> (100 mg/kg, oral, daily), or carboplatin (100 mg/kg, intraperitoneal, days 0 and 7); n = 5 mice/group. (D) N17350 efficacy 72 h after a single intra-tumoral injection across various xenograft models; n = 5–7 mice/group. (E) Cancer and non-cancer cells were isolated from OvCa patients, treated with N17350 (500 nM), doxorubicin (10 μM), or oxaliplatin (100 μM) for 24 h, and cell viability was assessed; n = 2–3/patient, n = 31–39 patients/group. (F) Representative N17350 killing curve (left) and eXEC50 values (right) for cancer cells and CD45 + immune cells isolated from the same tumor of OvCa patients ( n = 3/dose across patients). EC50 values for immune cells were assigned as >10,000 nM, as the maximal tested dose failed to achieve a response plateau, precluding accurate curve fitting. ∗ p < 0.05, two-way ANOVA (C and E), Student’s t test: unpaired (D) and paired (F). Results are mean ± SEM. Arrows indicate N17350 treatment. All replicates are independent biological replicates.
    Internal Standard Mrtx, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/internal standard mrtx/product/MedChemExpress
    Average 93 stars, based on 1 article reviews
    internal standard mrtx - by Bioz Stars, 2026-02
    93/100 stars
    		  Buy from Supplier
    mrtx 1257  (MedChemExpress)
    93
    MedChemExpress mrtx 1257
    N17350 broadly kills cancer cells while preserving immune cells (A and B) Various cancer cell lines and primary cancer cells from OvCa patients were treated with increasing doses of N17350 for 24 h, and the EC50 was determined (n = 2–6/dose). (A) Representative killing curves for OvCa patient cancer cells (left), lung cancer cells with distinct KRAS variants (middle), and other tumor types (right). (B) Summary of EC50 values (left) and cancer-cell-type origin (right). (C) Representative tumor growth curve for NCI-H358 and NCI-H2122 tumors (non-small cell lung cancer) treated with N17350 (400 μg/100 mm 3 , intra-tumoral), <t>MRTX1257</t> (100 mg/kg, oral, daily), or carboplatin (100 mg/kg, intraperitoneal, days 0 and 7); n = 5 mice/group. (D) N17350 efficacy 72 h after a single intra-tumoral injection across various xenograft models; n = 5–7 mice/group. (E) Cancer and non-cancer cells were isolated from OvCa patients, treated with N17350 (500 nM), doxorubicin (10 μM), or oxaliplatin (100 μM) for 24 h, and cell viability was assessed; n = 2–3/patient, n = 31–39 patients/group. (F) Representative N17350 killing curve (left) and eXEC50 values (right) for cancer cells and CD45 + immune cells isolated from the same tumor of OvCa patients ( n = 3/dose across patients). EC50 values for immune cells were assigned as >10,000 nM, as the maximal tested dose failed to achieve a response plateau, precluding accurate curve fitting. ∗ p < 0.05, two-way ANOVA (C and E), Student’s t test: unpaired (D) and paired (F). Results are mean ± SEM. Arrows indicate N17350 treatment. All replicates are independent biological replicates.
    Mrtx 1257, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mrtx 1257/product/MedChemExpress
    Average 93 stars, based on 1 article reviews
    mrtx 1257 - by Bioz Stars, 2026-02
    93/100 stars
    		  Buy from Supplier
    mrtx  (MedChemExpress)
    93
    MedChemExpress mrtx
    N17350 broadly kills cancer cells while preserving immune cells (A and B) Various cancer cell lines and primary cancer cells from OvCa patients were treated with increasing doses of N17350 for 24 h, and the EC50 was determined (n = 2–6/dose). (A) Representative killing curves for OvCa patient cancer cells (left), lung cancer cells with distinct KRAS variants (middle), and other tumor types (right). (B) Summary of EC50 values (left) and cancer-cell-type origin (right). (C) Representative tumor growth curve for NCI-H358 and NCI-H2122 tumors (non-small cell lung cancer) treated with N17350 (400 μg/100 mm 3 , intra-tumoral), <t>MRTX1257</t> (100 mg/kg, oral, daily), or carboplatin (100 mg/kg, intraperitoneal, days 0 and 7); n = 5 mice/group. (D) N17350 efficacy 72 h after a single intra-tumoral injection across various xenograft models; n = 5–7 mice/group. (E) Cancer and non-cancer cells were isolated from OvCa patients, treated with N17350 (500 nM), doxorubicin (10 μM), or oxaliplatin (100 μM) for 24 h, and cell viability was assessed; n = 2–3/patient, n = 31–39 patients/group. (F) Representative N17350 killing curve (left) and eXEC50 values (right) for cancer cells and CD45 + immune cells isolated from the same tumor of OvCa patients ( n = 3/dose across patients). EC50 values for immune cells were assigned as >10,000 nM, as the maximal tested dose failed to achieve a response plateau, precluding accurate curve fitting. ∗ p < 0.05, two-way ANOVA (C and E), Student’s t test: unpaired (D) and paired (F). Results are mean ± SEM. Arrows indicate N17350 treatment. All replicates are independent biological replicates.
    Mrtx, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mrtx/product/MedChemExpress
    Average 93 stars, based on 1 article reviews
    mrtx - by Bioz Stars, 2026-02
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    N17350 broadly kills cancer cells while preserving immune cells (A and B) Various cancer cell lines and primary cancer cells from OvCa patients were treated with increasing doses of N17350 for 24 h, and the EC50 was determined (n = 2–6/dose). (A) Representative killing curves for OvCa patient cancer cells (left), lung cancer cells with distinct KRAS variants (middle), and other tumor types (right). (B) Summary of EC50 values (left) and cancer-cell-type origin (right). (C) Representative tumor growth curve for NCI-H358 and NCI-H2122 tumors (non-small cell lung cancer) treated with N17350 (400 μg/100 mm 3 , intra-tumoral), MRTX1257 (100 mg/kg, oral, daily), or carboplatin (100 mg/kg, intraperitoneal, days 0 and 7); n = 5 mice/group. (D) N17350 efficacy 72 h after a single intra-tumoral injection across various xenograft models; n = 5–7 mice/group. (E) Cancer and non-cancer cells were isolated from OvCa patients, treated with N17350 (500 nM), doxorubicin (10 μM), or oxaliplatin (100 μM) for 24 h, and cell viability was assessed; n = 2–3/patient, n = 31–39 patients/group. (F) Representative N17350 killing curve (left) and eXEC50 values (right) for cancer cells and CD45 + immune cells isolated from the same tumor of OvCa patients ( n = 3/dose across patients). EC50 values for immune cells were assigned as >10,000 nM, as the maximal tested dose failed to achieve a response plateau, precluding accurate curve fitting. ∗ p < 0.05, two-way ANOVA (C and E), Student’s t test: unpaired (D) and paired (F). Results are mean ± SEM. Arrows indicate N17350 treatment. All replicates are independent biological replicates.

    Journal: Cell Reports Medicine

    Article Title: Developing a therapeutic elastase that stimulates anti-tumor immunity by selectively killing cancer cells

    doi: 10.1016/j.xcrm.2025.102446

    Figure Lengend Snippet: N17350 broadly kills cancer cells while preserving immune cells (A and B) Various cancer cell lines and primary cancer cells from OvCa patients were treated with increasing doses of N17350 for 24 h, and the EC50 was determined (n = 2–6/dose). (A) Representative killing curves for OvCa patient cancer cells (left), lung cancer cells with distinct KRAS variants (middle), and other tumor types (right). (B) Summary of EC50 values (left) and cancer-cell-type origin (right). (C) Representative tumor growth curve for NCI-H358 and NCI-H2122 tumors (non-small cell lung cancer) treated with N17350 (400 μg/100 mm 3 , intra-tumoral), MRTX1257 (100 mg/kg, oral, daily), or carboplatin (100 mg/kg, intraperitoneal, days 0 and 7); n = 5 mice/group. (D) N17350 efficacy 72 h after a single intra-tumoral injection across various xenograft models; n = 5–7 mice/group. (E) Cancer and non-cancer cells were isolated from OvCa patients, treated with N17350 (500 nM), doxorubicin (10 μM), or oxaliplatin (100 μM) for 24 h, and cell viability was assessed; n = 2–3/patient, n = 31–39 patients/group. (F) Representative N17350 killing curve (left) and eXEC50 values (right) for cancer cells and CD45 + immune cells isolated from the same tumor of OvCa patients ( n = 3/dose across patients). EC50 values for immune cells were assigned as >10,000 nM, as the maximal tested dose failed to achieve a response plateau, precluding accurate curve fitting. ∗ p < 0.05, two-way ANOVA (C and E), Student’s t test: unpaired (D) and paired (F). Results are mean ± SEM. Arrows indicate N17350 treatment. All replicates are independent biological replicates.

    Article Snippet: MRTX1257 , MedChemExpress , Cat#2206736-04-9 Lot#49910.

    Techniques: Preserving, Injection, Isolation